Incidence of major adverse cardiovascular events in patients with rheumatoid arthritis treated with JAK-inhibitors compared to bDMARDS: data from an international collaboration of registries (the “JAK-POT” study)
14/08/2023
R. Aymon1, D. Mongin1, S. A. Bergstra2, D. Choquette3, C. Codreanu4, R. L. Cordtz5, D. C. Diederik6, L. Dreyer5, O. Elkayam7, D. Huschek8, K. Hyrich9, F. Iannone10, N. Inanc11, L. Kearsley-Fleet9, T. K. Kvien12, B. Leeb13, G. Lukina14, D. Nordström15, F. Onen16, K. Pavelka17, M. Pombo-Suarez18, S. Aarrestad Provan12, A. M. Rodrigues19, Z. Rotar20, A. Strangfeld8, P. Verschueren6, J. Zavada17, D. Courvoisier1, A. Finckh1, K. Lauper1
EULAR 2023
DOI: 10.1136/annrheumdis-2023-eular.660
http://scientific.sparx-ip.net/archiveeular/?c=a&searchfor=jak%20pot&view=1&item=2023OP0219